Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Piscataqua Savings Bank

Piscataqua Savings Bank cut its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,684 shares of the biopharmaceutical company’s stock after selling 325 shares during the quarter. Piscataqua Savings Bank’s holdings in Bristol-Myers Squibb were worth $286,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Wealthspire Advisors LLC grew its holdings in Bristol-Myers Squibb by 0.6% during the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company’s stock worth $1,622,000 after acquiring an additional 170 shares in the last quarter. Edmp Inc. grew its stake in shares of Bristol-Myers Squibb by 0.4% during the fourth quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company’s stock worth $2,353,000 after purchasing an additional 171 shares in the last quarter. Bedel Financial Consulting Inc. grew its stake in shares of Bristol-Myers Squibb by 3.2% during the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company’s stock worth $340,000 after purchasing an additional 175 shares in the last quarter. King Wealth Management Group grew its stake in shares of Bristol-Myers Squibb by 2.6% during the fourth quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company’s stock worth $413,000 after purchasing an additional 182 shares in the last quarter. Finally, Signet Investment Advisory Group Inc. boosted its position in shares of Bristol-Myers Squibb by 2.3% during the 4th quarter. Signet Investment Advisory Group Inc. now owns 8,261 shares of the biopharmaceutical company’s stock worth $467,000 after acquiring an additional 189 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Stock Up 1.2%

Bristol-Myers Squibb stock opened at $48.42 on Friday. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The stock has a 50 day moving average of $49.34 and a two-hundred day moving average of $55.06. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The stock has a market capitalization of $98.54 billion, a price-to-earnings ratio of -10.95, a PEG ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same period last year, the company earned ($4.40) earnings per share. The company’s revenue for the quarter was down 5.6% on a year-over-year basis. As a group, research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BMY. Wall Street Zen cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday. Piper Sandler started coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price target for the company. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. UBS Group lowered their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.